middle.news
How Race Oncology’s RC220 Shields Hearts and Slays Cancer at ESMO 2025
9:06am on Monday 20th of October, 2025 AEDT
•
Healthcare
Read Story
How Race Oncology’s RC220 Shields Hearts and Slays Cancer at ESMO 2025
9:06am on Monday 20th of October, 2025 AEDT
Key Points
RC220 (E,E-bisantrene) reduces doxorubicin-induced heart damage
Combination therapy enhances anticancer activity across multiple cancer types
Mechanism involves DNA damage reduction in heart cells and MYC gene silencing
Preclinical data presented at major international oncology congress
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
RAC
OPEN ARTICLE